Key Takeaways
- Amazon One Medical rolled out an integrated GLP-1 weight management solution featuring virtual consultations, prescription services, and pharmacy delivery.
- Patients with insurance pay as little as $25 monthly; self-pay customers can access injectable treatments like Wegovy and Zepbound from $299/month.
- The e-commerce giant aims to bring same-day medication delivery to 4,500 cities by late 2026.
- Shares of Hims & Hers (HIMS) fell up to 6% during pre-market hours after the news broke.
- Analysts at Bank of America forecast the competitive threat could reduce HIMS’s GLP-1 business by 31%.
Amazon is entering the weight management pharmaceutical space in a big way. The retail giant announced Tuesday it’s launching a comprehensive GLP-1 program via Amazon One Medical, its healthcare division, combining obesity medication with pharmacy services and telemedicine appointments.
The offering includes access to leading brand-name treatments such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. For patients with insurance coverage, oral GLP-1 medications are available from just $25 monthly. Those paying out-of-pocket can obtain oral formulations starting at $149/month, with injectable versions like Wegovy and Zepbound priced from $299/month.
While these price points align with existing market rates, Amazon’s competitive advantage lies in convenience — leveraging its extensive distribution infrastructure for same-day delivery and creating a streamlined patient experience from initial consultation to ongoing prescription management.
Tanvi Patel, VP and GM of Amazon Pharmacy, explained the initiative aims to help patients “stay on those medications because they are delivered reliably directly to patients.”
The service is currently available nationwide and treats weight management as an ongoing chronic health condition rather than a short-term fix. The program encompasses preliminary health screenings, organized medical consultations, recurring follow-up appointments, and scientifically-backed treatment strategies.
Patients can also request prescription renewals on demand, with messaging consultations priced at $29 and video appointments at $49. Amazon intends to roll out same-day delivery capabilities to 4,500 metropolitan areas before 2026 concludes.
Competitive Pressure Hits HIMS
The news immediately impacted Hims & Hers Health negatively. HIMS shares tumbled as much as 6% before market open, though the decline moderated during regular trading hours. The sell-off signals investor anxiety about Amazon entering the affordable GLP-1 market segment where HIMS has established a presence.
The development comes at an awkward moment for HIMS. The telehealth company has recently been pivoting toward premium-priced branded obesity medications — precisely as Amazon introduces a rival comprehensive service. Bank of America analysts have cautioned this competitive entry could slash HIMS’s GLP-1 revenue stream by 31%.
Other companies connected to the weight loss pharmaceutical sector also experienced downward pressure Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
Amazon’s Growing Obesity Treatment Presence
Tuesday’s announcement represents Amazon’s latest expansion in GLP-1 medications. The company introduced same-day delivery for Novo Nordisk’s oral Wegovy product in January. By April, it had extended same-day service to include Eli Lilly’s new weight management pill, Foundayo, via its online pharmacy platform.
This week’s program launch consolidates those initiatives into a unified ecosystem — integrating primary healthcare, pharmaceutical fulfillment, and telehealth services in one package.
Among Wall Street analysts, AMZN enjoys a Strong Buy rating based on 45 analysts — including 42 Buy recommendations and 3 Hold ratings. The consensus price target of $286.74 suggests approximately 13% upside potential from present trading levels.
AMZN shares climbed roughly 1% in response to the announcement.
